


## Thalidomide-O-amido-PEG4-azide

Cat. No.:	HY-141011
CAS No.:	2411681-89-3
Molecular Formula:	C <sub>25</sub> H <sub>32</sub> N <sub>6</sub> O <sub>10</sub>
Molecular Weight:	576.56
Target:	E3 Ligase Ligand-Linker Conjugates; Apoptosis; Autophagy
Pathway:	PROTAC; Apoptosis; Autophagy
Storage:	<div>Powder</div> <div>-20°C 3 years</div> <div>4°C 2 years</div> <div>In solvent</div> <div>-80°C 6 months</div> <div>-20°C 1 month</div>



### BIOLOGICAL ACTIVITY

Description	<p>Thalidomide-O-amido-PEG4-azide is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs<sup>[1]</sup>.</p> <p>Thalidomide-O-amido-PEG4-azide is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAC) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.</p>
IC <sub>50</sub> & Target	Cereblon
In Vitro	<p>PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>

### REFERENCES

[1]. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA